MedDataX Logo

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Bioavailability, and Food-effects of EA1080 in Healthy Caucasian and Japanese Male Participants

NCT ID: NCT04223960

Last Updated: 2023-12-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

184 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-09

Study Completion Date

2023-08-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of the study is to evaluate the safety and tolerability of EA1080 following single and multiple ascending oral doses in healthy Caucasian and Japanese male participants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The drug being tested in this study is called EA1080. EA1080 is being tested to find a safe and well-tolerated dose in healthy Caucasian and Japanese male participants. The study consists of 2 parts as mentioned below:

Part A: This part of the study is fully adaptive and will be performed in three sub-parts as follows:

* Single ascending dose (SAD)
* Food Effect (FE) and optional bioavailability
* Multiple ascending dose (MAD)

Part B: This part of study is comprised of four sub-parts to assess Formulation E and Formulation F as follows:

* SAD
* An additional FE period in SAD cohorts (SAD-FE)
* Food Effect and bioavailability (FE/BA)
* MAD

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

EA1080 Pharmacokinetics Food effect study Pharmacodynamics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part A: SAD, EA1080 Formulation A in Healthy Caucasian Participants

Healthy Caucasian participants will receive EA1080 Formulation A or matching placebo orally, once on Day 1 of SAD part of the study. In SAD, there will be a maximum of 7 dose levels (three-four planned cohorts and three optional cohorts).

Group Type EXPERIMENTAL

EA1080

Intervention Type DRUG

EA1080 Formulation A.

EA1080-matching placebo

Intervention Type DRUG

EA1080-matching placebo.

Part A: SAD, EA1080 Formulation B in Healthy Caucasian Participants

Healthy Caucasian participants will receive EA1080 Formulation B or matching placebo orally, once on Day 1 of SAD part of the study. In SAD, there will be a maximum of 7 dose levels (three-four planned cohorts and three optional cohorts).

Group Type EXPERIMENTAL

EA1080

Intervention Type DRUG

EA1080 Formulation B.

EA1080-matching placebo

Intervention Type DRUG

EA1080-matching placebo.

Part A: SAD, EA1080 Formulation C in Healthy Caucasian Participants

Healthy Caucasian participants will receive EA1080 Formulation C or matching placebo orally, once on Day 1 of SAD part of the study. In SAD, there will be a maximum of 7 dose levels (three-four planned cohorts and three optional cohorts).

Group Type EXPERIMENTAL

EA1080

Intervention Type DRUG

EA1080 Formulation C.

EA1080-matching placebo

Intervention Type DRUG

EA1080-matching placebo.

Part A: SAD, EA1080 Formulation D in Healthy Caucasian Participants

Healthy Caucasian participants will receive EA1080 Formulation D or matching placebo orally, once on Day 1 of SAD part of the study. In SAD, there will be a maximum of 7 dose levels (three-four planned cohorts and three optional cohorts).

Group Type EXPERIMENTAL

EA1080

Intervention Type DRUG

EA1080 Formulation D.

EA1080-matching placebo

Intervention Type DRUG

EA1080-matching placebo.

Part A: SAD, EA1080 in Healthy Japanese Participants (Optional)

Healthy Japanese participants will receive any EA1080 formulation (Formulation A, Formulation B, Formulation C, and Formulation D) or matching placebo orally, once on Day 1 of SAD part of the study. There will be a maximum of six dose levels (three planned and three optional cohorts) per formulation.

Group Type EXPERIMENTAL

EA1080

Intervention Type DRUG

EA1080 Formulation A.

EA1080

Intervention Type DRUG

EA1080 Formulation B.

EA1080

Intervention Type DRUG

EA1080 Formulation C.

EA1080

Intervention Type DRUG

EA1080 Formulation D.

EA1080-matching placebo

Intervention Type DRUG

EA1080-matching placebo.

Part A: FE and Optional BA in Healthy Caucasian Participants

Healthy Caucasian participants will receive EA1080 on Day 1 and Day 8 in selected formulations (Formulation A, Formulation B, Formulation C, and Formulation D) in fed and fasted states. These formulations may be tested in any order or combination up to eight- way crossover design. The order will be dependent on the treatment sequence in which participants will be allocated to treatment. A washout period of 7 days will be maintained between the dosing days of each treatment periods.

Group Type EXPERIMENTAL

EA1080

Intervention Type DRUG

EA1080 Formulation A.

EA1080

Intervention Type DRUG

EA1080 Formulation B.

EA1080

Intervention Type DRUG

EA1080 Formulation C.

EA1080

Intervention Type DRUG

EA1080 Formulation D.

Part A: FE and Optional BA, in Healthy Japanese Participants

Healthy Japanese participants will receive EA1080 on Day 1 and Day 8 in selected formulations (Formulation A, Formulation B, Formulation C, and Formulation D) in fed and fasted states. These formulations may be tested in any order or combination up to four-way crossover design. The order will be dependent on the treatment sequence in which participants will be allocated to treatment. A washout period of 7 days will be maintained between the dosing days of each treatment periods.

Group Type EXPERIMENTAL

EA1080

Intervention Type DRUG

EA1080 Formulation A.

EA1080

Intervention Type DRUG

EA1080 Formulation B.

EA1080

Intervention Type DRUG

EA1080 Formulation C.

EA1080

Intervention Type DRUG

EA1080 Formulation D.

Part A: MAD, EA1080 Formulation A in Healthy Caucasian Participants

Healthy Caucasian participants will receive EA1080 Formulation A or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 21 in MAD part of the study. In MAD, there will be a maximum of 6 dose levels (three planned cohorts and three optional cohorts).

Group Type EXPERIMENTAL

EA1080

Intervention Type DRUG

EA1080 Formulation A.

EA1080-matching placebo

Intervention Type DRUG

EA1080-matching placebo.

Part A: MAD, EA1080 Formulation B in Healthy Caucasian Participants

Healthy Caucasian participants will receive EA1080 Formulation B or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 21 in MAD part of the study. In MAD, there will be a maximum of 6 dose levels (three planned cohorts and three optional cohorts).

Group Type EXPERIMENTAL

EA1080

Intervention Type DRUG

EA1080 Formulation B.

EA1080-matching placebo

Intervention Type DRUG

EA1080-matching placebo.

Part A: MAD, EA1080 Formulation C in Healthy Caucasian Participants

Healthy Caucasian participants will receive EA1080 Formulation C or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 21 in MAD part of the study. In MAD, there will be a maximum of 6 dose levels (three planned cohorts and three optional cohorts).

Group Type EXPERIMENTAL

EA1080

Intervention Type DRUG

EA1080 Formulation C.

EA1080-matching placebo

Intervention Type DRUG

EA1080-matching placebo.

Part A: MAD, EA1080 Formulation D in Healthy Caucasian Participants

Healthy Caucasian participants will receive EA1080 Formulation D or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 21 in MAD part of the study. In MAD, there will be a maximum of 6 dose levels (three planned dose level and three optional).

Group Type EXPERIMENTAL

EA1080

Intervention Type DRUG

EA1080 Formulation D.

EA1080-matching placebo

Intervention Type DRUG

EA1080-matching placebo.

Part A: MAD, EA1080 in Healthy Japanese Participants (Optional)

Healthy Japanese participants will receive any EA1080 formulation (Formulation A, Formulation B, Formulation C, and Formulation D) or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 21 in MAD part of the study. In MAD, there will be a maximum of 6 dose levels (three planned dose level and three optional) per formulation.

Group Type EXPERIMENTAL

EA1080

Intervention Type DRUG

EA1080 Formulation A.

EA1080

Intervention Type DRUG

EA1080 Formulation B.

EA1080

Intervention Type DRUG

EA1080 Formulation C.

EA1080

Intervention Type DRUG

EA1080 Formulation D.

EA1080-matching placebo

Intervention Type DRUG

EA1080-matching placebo.

Part B: SAD, EA1080 Formulation E in Healthy Caucasian Participants

Healthy Caucasian participants will receive EA1080 Formulation E or matching placebo orally, once on Day 1 of SAD part of the study (three planned cohorts and six optional cohorts).

Group Type EXPERIMENTAL

EA1080-matching placebo

Intervention Type DRUG

EA1080-matching placebo.

EA1080

Intervention Type DRUG

EA1080 Formulation E.

Part B: SAD, EA1080 Formulation E in Healthy Japanese Participants

Healthy Japanese participants will receive EA1080 Formulation E or matching placebo orally, once on Day 1 of SAD part of the study (three planned cohorts and six optional cohorts).

Group Type EXPERIMENTAL

EA1080-matching placebo

Intervention Type DRUG

EA1080-matching placebo.

EA1080

Intervention Type DRUG

EA1080 Formulation E.

Part B: SAD, EA1080 Formulation F in Healthy Caucasian Participants

Healthy Caucasian participants will receive EA1080 Formulation F or matching placebo orally, once on Day 1 of SAD part of the study (three planned cohorts and six optional cohorts).

Group Type EXPERIMENTAL

EA1080-matching placebo

Intervention Type DRUG

EA1080-matching placebo.

EA1080

Intervention Type DRUG

EA1080 Formulation F.

Part B: SAD, EA1080 Formulation F in Healthy Japanese Participants

Healthy Japanese participants will receive EA1080 Formulation E or matching placebo orally, once on Day 1 of SAD part of the study (three planned cohorts and six optional cohorts).

Group Type EXPERIMENTAL

EA1080-matching placebo

Intervention Type DRUG

EA1080-matching placebo.

EA1080

Intervention Type DRUG

EA1080 Formulation F.

Part B: SAD-FE, EA1080 Formulation E in Healthy Caucasian Participants

Healthy Caucasian participants will receive EA1080 Formulation E or matching placebo on Day 1 in fasted state followed by EA1080 Formulation E on Day 8 in fed states. A washout period of 6 days will be maintained between the dosing days.

Group Type EXPERIMENTAL

EA1080-matching placebo

Intervention Type DRUG

EA1080-matching placebo.

EA1080

Intervention Type DRUG

EA1080 Formulation E.

Part B: SAD-FE, EA1080 Formulation E in Healthy Japanese Participants

Healthy Japanese participants will receive EA1080 Formulation E or matching placebo on Day 1 in fasted state followed by EA1080 Formulation E on Day 8 in fed states. A washout period of 6 days will be maintained between the dosing days.

Group Type EXPERIMENTAL

EA1080-matching placebo

Intervention Type DRUG

EA1080-matching placebo.

EA1080

Intervention Type DRUG

EA1080 Formulation E.

Part B: SAD-FE, EA1080 Formulation F in Healthy Caucasian Participants

Healthy Caucasian participants will receive EA1080 Formulation F or matching placebo on Day 1 in fasted state followed by EA1080 Formulation F on Day 8 in fed states. A washout period of 6 days will be maintained between the dosing days.

Group Type EXPERIMENTAL

EA1080-matching placebo

Intervention Type DRUG

EA1080-matching placebo.

EA1080

Intervention Type DRUG

EA1080 Formulation F.

Part B: SAD-FE, EA1080 Formulation F in Healthy Japanese Participants

Healthy Japanese participants will receive EA1080 Formulation F or matching placebo on Day 1 in fasted state followed by EA1080 Formulation F on Day 8 in fed states. A washout period of 6 days will be maintained between the dosing days.

Group Type EXPERIMENTAL

EA1080-matching placebo

Intervention Type DRUG

EA1080-matching placebo.

EA1080

Intervention Type DRUG

EA1080 Formulation F.

Part B: FE/BA, in Healthy Caucasian Participants

Healthy Caucasian participants will receive EA1080 on Days 1 8 and 15 in selected formulations (Formulation E in fasted state, Formulation F in fasted state, Formulation F in fed state). These formulations will be tested in a crossover design. The order will be dependent on the treatment sequence in which participants will be allocated to treatment. A washout period of 6 days will be maintained between the dosing days of each treatment periods.

Group Type EXPERIMENTAL

EA1080

Intervention Type DRUG

EA1080 Formulation E.

EA1080

Intervention Type DRUG

EA1080 Formulation F.

Part B: FE/BA, in Healthy Japanese Participants

Healthy Japanese participants will receive EA1080 on Days 1 8 and 15 in selected formulations (Formulation E in fasted state, Formulation F in fasted state, Formulation F in fed state). These formulations will be tested in a crossover design. The order will be dependent on the treatment sequence in which participants will be allocated to treatment. A washout period of 6 days will be maintained between the dosing days of each treatment periods.

Group Type EXPERIMENTAL

EA1080

Intervention Type DRUG

EA1080 Formulation E.

EA1080

Intervention Type DRUG

EA1080 Formulation F.

Part B: MAD, EA1080 Formulation E in Healthy Caucasian Participants

Healthy Caucasian participants will receive EA1080 Formulation E or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 17 in Part B, MAD of the study. In Part B, MAD, there will be a maximum of 6 dose levels (one-three planned dose level and six optional).

Group Type EXPERIMENTAL

EA1080-matching placebo

Intervention Type DRUG

EA1080-matching placebo.

EA1080

Intervention Type DRUG

EA1080 Formulation E.

Part B: MAD, EA1080 Formulation E in Healthy Japanese Participants

Healthy Japanese participants will receive EA1080 Formulation E or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 17 in Part B, MAD of the study. In Part B, MAD, there will be a maximum of 6 dose levels (one-three planned dose level and six optional).

Group Type EXPERIMENTAL

EA1080-matching placebo

Intervention Type DRUG

EA1080-matching placebo.

EA1080

Intervention Type DRUG

EA1080 Formulation E.

Part B: MAD, EA1080 Formulation F in Healthy Caucasian Participants

Healthy Caucasian participants will receive EA1080 Formulation F or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 17 in Part B, MAD of the study. In Part B, MAD, there will be a maximum of 6 dose levels (one-three planned dose level and six optional).

Group Type EXPERIMENTAL

EA1080-matching placebo

Intervention Type DRUG

EA1080-matching placebo.

EA1080

Intervention Type DRUG

EA1080 Formulation F.

Part B: MAD, EA1080 Formulation F in Healthy Japanese Participants

Healthy Japanese participants will receive EA1080 Formulation F or matching placebo orally, once on Day 1 then multiple daily doses beginning on Day 8 up to Day 17 in Part B, MAD of the study. In Part B, MAD, there will be a maximum of 6 dose levels (one-three planned dose level and six optional).

Group Type EXPERIMENTAL

EA1080-matching placebo

Intervention Type DRUG

EA1080-matching placebo.

EA1080

Intervention Type DRUG

EA1080 Formulation F.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EA1080

EA1080 Formulation A.

Intervention Type DRUG

EA1080

EA1080 Formulation B.

Intervention Type DRUG

EA1080

EA1080 Formulation C.

Intervention Type DRUG

EA1080

EA1080 Formulation D.

Intervention Type DRUG

EA1080-matching placebo

EA1080-matching placebo.

Intervention Type DRUG

EA1080

EA1080 Formulation E.

Intervention Type DRUG

EA1080

EA1080 Formulation F.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Participants must meet all of the following criteria to be eligible for enrolment in this study:

1. Participants in Caucasian cohorts must be healthy males, aged greater than or equal (\>=) 18 to less than or equal to (\<=) 45 years at the date of signing informed consent
2. Participants in Japanese cohorts must be healthy males, aged \>=20 to \<=45 years at the date of signing informed consent
3. Participants must have a body mass index (BMI) between 18.5-25.0 kilogram per square meter (kg/m\^2) inclusive at screening, Day -3, Day -2 or Day -1.

Exclusion Criteria

Participants will be excluded from enrolment in this study if they meet any of the following criteria:

1. Positive test for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening
2. Consumption of herbal remedies or dietary supplements containing St. John's Wort 30 days before the first day of dosing
3. Has donated or lost 400 milliliter (mL) blood or more within the last 16 weeks preceding the first day of dosing
4. An inability to follow a standardised diet and meal schedule or inability to fast, as required during the study
5. Prior screen failure (where the cause of the screen failure is not deemed to be temporary), randomisation, participation, or enrolment in this study. Participants who initially failed due to temporary non-medically significant issues are eligible for re-screening once the cause has resolved
6. Participants with veins on either arm that are unsuitable for intravenous puncture or cannulation (example, veins that are difficult to locate, or a tendency to rupture during puncture)
7. Participants with any medical condition which may cause raised intracranial pressure, participants with new or changing headaches, and participants with history of head or spinal trauma
8. An absolute lymphocyte count below 0.9\*10\^9 per liter (/L) at screening or on Day -1
9. Participants in receipt of any vaccination for Corona virus disease (COVID-19) within 14 days prior to the first dose administration.
10. History of COVID-19 polymerase chain reaction (PCR) positivity within 3 months of Day 1, suspected COVID-19 based on clinical presentation within 3 months of Day 1, or presence of clinically relevant long term sequelae of COVID-19.
11. Unwillingness to receive COVID-19 testing per local or site COVID-19 guidance.
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

EA Pharma Co., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Richmond Pharmacology Ltd

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2019-001886-34

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

EA1080-CP1

Identifier Type: -

Identifier Source: org_study_id